Subsequently, we explored whether the levels of PD1+CD8+ T‐cells and CD163+ TAM infiltration in the TME could be used to optimize treatment choices for HER2‐altered NSCLC. This evidence concerns the gene CD163 and non-small cell lung carcinoma.